Trinity Biotech plc TRIB announced compelling positive clinical trial results with respect to its next-generation continuous glucose monitoring (CGM) technology, CGM+, on Tuesday. The trial data ...

Clinical data confirms elimination of requirement for finger-stick calibration, de-risking pathway to commercialization for ...

The company said its CGM+ system can deliver accurate readings across a 15-day lifespan, while also employing fewer ...

An update from Trinity Biotech ( ($TRIB) ) is now available. On August 12, 2025, Trinity Biotech announced breakthrough clinical trial results for ...

Trinity Biotech plc (NASDAQ: TRIB) stock rose 4.4% following the company’s announcement of positive clinical trial results for its next-generation continuous gl ...

Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 News provided by Trinity Biotech plc Jan 28, 2025, 7:20 AM ET ...

David Ouston, Biosensor Marketing Director of Trinity Biotech, said, “We’ve made significant progress in the development of our next generation CGM, with an innovative reimagining of our ...

Trinity Biotech anticipates commercial launch of CGM+ in mid-2026, opening multiple revenue streams, including device sales, AI analytics subscriptions and strategic partnerships with healthcare ...

-Repositioning to a rapidly expanding biosensor market with potential for significant growth for the company as part of a revised strategy under our new management -Upfront payment of $12.5 ...

Trinity Biotech plc has announced encouraging results from its recent pre-pivotal clinical trial of its next-generation continuous glucose monitoring (CGM) system, targeting diabetes management ...